Standing on shaky ground: US patent-eligibility of isolated DNA and genetic diagnostics after AMP v USPTO - Part IV
As discussed in the previous issues of QMJIP, the Federal Circuit's decisions in Myriad I-2 and II3 appear to provide considerable prospects for patentees, as clever claim drafting may still help to avoid most patent-eligibility traps set by the much debated US Supreme Court decision in Prometheus.(4) Yet, the split opinions also contain elusive reasoning by each of the three judges. The questions
